Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350726 | 0.82 | CSNK2B (0.42) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL3869722 | 0.73 | LMNA (0.43) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL25244213 | 0.73 | CA1 (0.48) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7076930 | 0.73 | KDM4E (0.72) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7497574 | 0.70 | SLC2A1 (0.52) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL14653052 | 0.69 | ALDH1A1 (0.42) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL8083830 | 0.68 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL3871079 | 0.68 | ALDH1A1 (0.39) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7701080 | 0.67 | LRRK2 (0.56) | KDM4E | |
| SCHEMBL4074462 | 0.64 | ALDH1A1 (0.41) | KDM4EALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432715-B1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1432715-B1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-7312224-B2 | Pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2007-12-25 | — | — | US | disclosed |
| US-7312224-B2 | Pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2007-12-25 | — | — | US | disclosed |
| US-20040242595-A1 | Pyrimidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1432715-A2 | PYRIMIDINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003031447-A2 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031447-A2 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242595-A1 | Pyrimidine derivatives | TYMP, DPYD, TYMS | KDM4E 2620/4885ALDH1A1 671/4885HSD17B10 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.